All In MedTech

Device Trial Radar · NCT07851038

Focused Ultrasound for Behavioral Health

Bayesian-Optimized Dose-Finding of ATTN201 Focused Ultrasound for Behavioral Health

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Apr 5, 2028

Study completion May 17, 2028

Sponsor

Lead sponsor
Attune Neurosciences IncNot on our public-company list
Sponsor type
Industry
Collaborators
University of California, San Francisco; University of Pennsylvania
First posted
Oct 1, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Crossover
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.

Conditions

  • Depression
  • Anxiety
  • Obsessive Compulsive Disorder (OCD)

Interventions

  • ATTN201 head-worn focused ultrasoundDevice

    ATTN201 head-worn focused ultrasound

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-specific transdiagnostic score (TDx) at 1 week after stimulationTime frame: 1 week after each stimulation session

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Attune Neurosciences, Inc.

    San Francisco, California · Not yet recruiting

  • Attune, San Francisco Clinical Research Center

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.